Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Puxitatug Samrotecan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Puxitatug Samrotecan is expected to reach an annual total of $31 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Puxitatug Samrotecan Overview
Puxitatug samrotecan (AZD-8205) is under development for the treatment of recurrent or metastatic solid tumors including breast cancer, cholangiocarcinoma, ovarian, biliary tract cancer, fallopian tube, peritoneal and endometrial cancers. The therapeutic candidate is an antibody-drug conjugate (ADC) specific to B7-H4 that uses a linker drug consisting of topoisomerase I linker-warhead. It is administered through intravenous route.
It was also under development for the treatment of triple-negative breast cancer (TNBC).
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$44,351 million for the fiscal year ended December 2022 (FY2022), an increase of 18.5% over FY2021. In FY2022, the company’s operating margin was 8.5%, compared to an operating margin of 2.8% in FY2021. In FY2022, the company recorded a net margin of 7.4%, compared to a net margin of 0.3% in FY2021. The company reported revenues of US$11,416 million for the second quarter ended June 2023, an increase of 4.9% over the previous quarter.
For a complete picture of Puxitatug Samrotecan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.